Natera, Inc. (NASDAQ:NTRA) CEO Sells $468,111.60 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,960 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $468,111.60. Following the completion of the transaction, the chief executive officer now directly owns 189,762 shares of the company’s stock, valued at $22,431,766.02. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, October 21st, Steven Leonard Chapman sold 1,709 shares of Natera stock. The shares were sold at an average price of $120.76, for a total transaction of $206,378.84.
• On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The stock was sold at an average price of $130.40, for a total transaction of $589,799.20.
• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52.
• On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The stock was sold at an average price of $118.91, for a total transaction of $663,874.53.

Natera Stock Performance

NASDAQ NTRA opened at $124.16 on Friday. Natera, Inc. has a fifty-two week low of $40.17 and a fifty-two week high of $133.54. The firm has a market capitalization of $15.36 billion, a P/E ratio of -50.68 and a beta of 1.53. The stock’s fifty day moving average is $123.37 and its two-hundred day moving average is $111.99. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. During the same quarter in the prior year, the firm posted ($0.97) earnings per share. Natera’s quarterly revenue was up 58.1% on a year-over-year basis. On average, research analysts anticipate that Natera, Inc. will post -1.96 earnings per share for the current year.

Institutional Trading of Natera

Several institutional investors have recently made changes to their positions in NTRA. Wealth Enhancement Advisory Services LLC raised its position in Natera by 25.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 5,776 shares of the medical research company’s stock valued at $528,000 after purchasing an additional 1,155 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Natera by 19.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 863,406 shares of the medical research company’s stock valued at $78,967,000 after buying an additional 143,246 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. purchased a new position in Natera during the first quarter worth about $33,956,000. Maryland State Retirement & Pension System increased its position in shares of Natera by 11.2% during the first quarter. Maryland State Retirement & Pension System now owns 8,535 shares of the medical research company’s stock valued at $761,000 after acquiring an additional 857 shares during the last quarter. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of Natera in the 1st quarter valued at approximately $1,392,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of recent analyst reports. Robert W. Baird increased their price target on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Stephens reissued an “overweight” rating and issued a $125.00 price target on shares of Natera in a research note on Friday, August 9th. Morgan Stanley upped their price objective on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Canaccord Genuity Group increased their price objective on shares of Natera from $145.00 to $150.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Sanford C. Bernstein boosted their target price on shares of Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $125.69.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.